{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:41:48Z","timestamp":1790109708904,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Overactive bladder is a common chronic urological disorder in children, liable to impact normal social activities, disrupt sleep and even impair self-esteem. We aimed to evaluate the efficacy and safety of solifenacin combined with biofeedback for paediatric overactive bladder.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Forty-five children with overactive bladder were enrolled and divided into three groups: 15 patients in Group A were treated with solifenacin, 15 cases in Group B with biofeedback, and the other 15 patients in Group C with the combination of solifenacin plus biofeedback. Each group was subdivided into the non-urge incontinence (non-UI) and urge incontinence (UI) groups. The remission rates were compared among the three groups at 2, 4, 8 and 12\u00a0weeks from the beginning of treatment. The side effects of solifenacin were recorded and followed up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>After 2\u00a0weeks since initial treatment, the complete response rates were 33.3% (5\/15), 20.0% (3\/15), and 53.3% (8\/15) in the three groups. At 4\u00a0weeks, the complete remission rates were 46.7% (7\/15), 33.3% (5\/15), and 60.0% (9\/15) respectively. Moreover, the complete remission rates of the UI groups were higher than the non-UI groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). At 8\u00a0weeks, the complete response rates were 53.3% (8\/15), 40.0% (6\/15), and 67.7% (10\/15). At 12\u00a0weeks, the complete response rates were 67.8% (10\/15), 60.0% (9\/15), and 86.7% (13\/15). The complete response rates were higher and urodynamic parameters were improved obviously in group C than the other two groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) during the follow-ups. The median voiding frequency decreased and median functional bladder capacity increased obviously in Group C after 4\u00a0weeks (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Dry mouth was observed in 2 patients (4.4%). 2 patients experienced constipation (4.4%), and neither case was severe. The symptoms of these four patients had relieved by reducing the dose of solifenacin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Solifenacin combined with biofeedback had good efficacy and compliance for children experiencing overactive bladder. It took only 2\u00a0weeks to achieve the complete response rate over 50%, especially for the improvement of UI symptoms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-024-01486-9","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T10:02:19Z","timestamp":1714039339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder"],"prefix":"10.1186","volume":"24","author":[{"given":"Yan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"1486_CR1","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nrurol.2016.152","volume":"13","author":"I Franco","year":"2016","unstructured":"Franco I. Overactive bladder in children. Nat Rev Urol. 2016;13:520\u201332.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1486_CR2","doi-asserted-by":"publisher","first-page":"e057736","DOI":"10.1136\/bmjopen-2021-057736","volume":"12","author":"B Zhu","year":"2022","unstructured":"Zhu B, Liu Y, Wang H, Duan F, Mi L, Liang Y. Clinical guidelines of UTIs in children: quality appraisal with AGREE II and recommendations analysis. BMJ Open. 2022;12(4):e057736.","journal-title":"BMJ Open"},{"key":"1486_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/nau.10099","volume":"22","author":"GA Digesu","year":"2003","unstructured":"Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: Do we need urodynamics? Neurourol Urodyn. 2003;22:105\u20138.","journal-title":"Neurourol Urodyn"},{"key":"1486_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0022-5347(05)63948-1","volume":"169","author":"AJ Flisser","year":"2003","unstructured":"Flisser AJ, Walmsley K, Blaivas JG. Urodynamic classification of patients with symptoms of overactive bladder. J Urol. 2003;169:529\u201334.","journal-title":"J Urol"},{"issue":"4","key":"1486_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/nau.22751","volume":"35","author":"PF Austin","year":"2016","unstructured":"Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children\u2019s Continence Society. Neurourol Urodyn. 2016;35(4):471\u201381.","journal-title":"Neurourol Urodyn"},{"key":"1486_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.urology.2008.06.063","volume":"73","author":"JM Chung","year":"2009","unstructured":"Chung JM, Lee SD, Kang DI, Kwon DD, Kim KS, Kim SY, et al. Prevalence and associated factors of overactive bladder in Korean children 5\u201313 years old: a nationwide multicenter study. Urology. 2009;73:63\u20137.","journal-title":"Urology"},{"key":"1486_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1046\/j.1532-5415.2002.50204.x","volume":"50","author":"PS Goode","year":"2002","unstructured":"Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002;50:808\u201316.","journal-title":"J Am Geriatr Soc"},{"key":"1486_CR8","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1001\/jama.288.18.2293","volume":"288","author":"KL Burgio","year":"2002","unstructured":"Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: A randomized controlled trial. JAMA. 2002;288:2293\u20139.","journal-title":"JAMA"},{"issue":"4","key":"1486_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.urology.2014.12.031","volume":"85","author":"H Tugtepe","year":"2015","unstructured":"Tugtepe H, Thomas DT, Ergun R, Abdullayev T, Kastarli C, Kaynak A, et al. Comparison of Biofeedback Therapy in Children with Treatment-refractory Dysfunctional Voiding and Overactive Bladder. Urol. 2015;85(4):900\u20134.","journal-title":"Urol"},{"key":"1486_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11934-009-0003-1","volume":"10","author":"SJ Hodges","year":"2009","unstructured":"Hodges SJ, Atala A. A randomized placebo-controlled study of the efficacy of antimuscarinics in the treatment of pediatric overactive bladder and incontinence. Curr Urol Rep. 2009;10:6\u20137.","journal-title":"Curr Urol Rep"},{"key":"1486_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.eururo.2016.08.061","volume":"71","author":"D Newgreen","year":"2017","unstructured":"Newgreen D, Bosman B, Hollestein-Havelaar A, Dahler E, Besuyen R, Sawyer W, et al. Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial. Eur Urol. 2017;71:483\u201390.","journal-title":"Eur Urol"},{"issue":"Suppl 4","key":"1486_CR12","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.juro.2009.05.100","volume":"182","author":"P Hoebeke","year":"2009","unstructured":"Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E, et al. Solifenacin for therapy resistant overactive bladder. J Urol. 2009;182(Suppl 4):2040\u20134.","journal-title":"J Urol"},{"key":"1486_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1532-5415.2000.tb04692.x","volume":"48","author":"KL Burgio","year":"2000","unstructured":"Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000;48:370\u20134.","journal-title":"J Am Geriatr Soc"},{"key":"1486_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1442-2042.2006.01217.x","volume":"13","author":"M Kajiwara","year":"2006","unstructured":"Kajiwara M, Inoue K, Kato M, Usui A, Kurihara M, Usui T. Nocturnal enuresis and overactive bladder in children: an epidemiological study. Int J Urol. 2006;13:36\u201341.","journal-title":"Int J Urol"},{"key":"1486_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fped.2019.00298","volume":"7","author":"M Fuentes","year":"2019","unstructured":"Fuentes M, Magalhes J, Barroso U. Diagnosis and Management of Bladder Dysfunction in Neurologically Normal Children. Front Pediatr. 2019;7:298.","journal-title":"Front Pediatr"},{"key":"1486_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/nau.22446","volume":"33","author":"JD van Gool","year":"2014","unstructured":"van Gool JD, de Jong TPVM, Winkler-Seinstra P, Tamminen-M\u00f6bius T, Lax H, Hirche H, et al. Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence. Neurourol Urodyn. 2014;33:482\u20137.","journal-title":"Neurourol Urodyn."},{"key":"1486_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","volume":"93","author":"CR Chapple","year":"2004","unstructured":"Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303\u201310.","journal-title":"BJU Int"},{"key":"1486_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0302-2838(02)00177-X","volume":"41","author":"K Kreder","year":"2002","unstructured":"Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol. 2002;41:588\u201395.","journal-title":"Eur Urol"},{"key":"1486_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4065\/78.6.687","volume":"78","author":"AC Diokno","year":"2003","unstructured":"Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687\u201395.","journal-title":"Mayo Clin Proc"},{"key":"1486_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00467-007-0691-z","volume":"23","author":"C Verpoorten","year":"2008","unstructured":"Verpoorten C, Buyse GM. The neurogenic bladder: medical treatment. Pediatr Nephrol. 2008;23:717\u201325.","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"1486_CR21","first-page":"379","volume":"107","author":"DO Sussman","year":"2007","unstructured":"Sussman DO. Overactive bladder: treatment options in primary care medicine. J Am Osteopath Assoc. 2007;107(9):379\u201385.","journal-title":"J Am Osteopath Assoc"},{"key":"1486_CR22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.eururo.2007.05.027","volume":"52","author":"CR Chapple","year":"2007","unstructured":"Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, et al. Treatment outcomes in the STAR study: A subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol. 2007;52:1195\u2013203.","journal-title":"Eur Urol"},{"issue":"2","key":"1486_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3346\/jkms.2017.32.2.329","volume":"32","author":"SD Lee","year":"2017","unstructured":"Lee SD, Chung JM, Kang DI, Ryu DS, Cho WY, Park S. Efficacy and tolerability of solifenacin 5 mg fixed dose in Korean children with newly diagnosed idiopathic overactive bladde: a multicenter prospective study. J Korean Med Sci. 2017;32(2):329\u201334.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"1486_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","volume":"18","author":"M Chancellor","year":"2012","unstructured":"Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18(2):167\u201374.","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"1486_CR25","doi-asserted-by":"publisher","first-page":"180.e1","DOI":"10.1016\/j.jpurol.2019.12.012","volume":"16","author":"I Franco","year":"2020","unstructured":"Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, et al. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatr Urol. 2020;16(2):180.e1-180.e8.","journal-title":"J Pediatr Urol"},{"key":"1486_CR26","first-page":"S69","volume":"34","author":"O Yamaguchi","year":"2006","unstructured":"Yamaguchi O. Long-term safety and efficacy of solifenacin succinate in patients with overactive bladder. Jpn Pharmacol Ther. 2006;34:S69-86.","journal-title":"Jpn Pharmacol Ther"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01486-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01486-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01486-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T10:09:56Z","timestamp":1714039796000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01486-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01486-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"12 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research in the manuscript has been performed in accordance with the Declaration of Helsinki and approved by the ethics committee of West China Second University Hospital of Sichuan University. Informed consent was obtained from all of the children\u2019s parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}